How Cancer Treatment Became Personal: From Chemotherapy to Precision Immunotherapy

Surgery and radiation acted locally, but nitrogen mustard showed that chemicals could reach dispersed cancer cells. The responses were temporary and the drug damaged healthy dividing tissue, establishing both the promise and the central toxicity of chemotherapy.

The remissions did not last, but the study converted chemotherapy from an accidental observation into a strategy based on cell biology. It also made clear that a single drug would rarely suppress an evolving cancer indefinitely.

This was a decisive change from temporary tumour shrinkage. The result did not mean all solid tumours were equally vulnerable, but it established cure as a realistic objective for selected cancers and encouraged combination regimens designed to prevent resistance.

The hybridoma technique did not immediately deliver a cancer drug. It provided the manufacturing foundation for antibodies that could bind proteins on tumour cells or alter immune signalling. Turning the platform into safe, durable medicines required another two decades of engineering.

Unlike chemotherapy, rituximab selected cells carrying a defined surface protein and recruited biological mechanisms to eliminate them. Targeting improved selectivity but did not eliminate toxicity, and cancers could resist treatment by changing the target or surviving through other pathways.

The drug matched a molecular abnormality to an inhibitor designed around its activity, transforming outcomes for many patients with chronic myeloid leukemia. Its success helped establish the model of testing a tumour for a dependency and selecting treatment accordingly, while later resistance showed that even precise targets can evolve.

The treatment personalized manufacturing around each patient rather than creating one identical product for everyone. Its benefit was modest and limited to a defined setting, but it demonstrated that an individualized immune product could be manufactured, regulated and delivered as medicine.

Checkpoint inhibitors can produce durable responses because immune cells adapt and persist, but only a subset of patients benefits. Removing immune restraints can also cause serious inflammation in healthy organs, making biomarkers and careful management central to treatment.

CAR T therapy combined gene engineering, cell manufacturing and immunology in one individualized treatment. It could rescue some patients after other options failed, but severe immune reactions, neurological toxicity, cost and difficult manufacturing limited access, while most solid tumours remained resistant.

Cancer classification had traditionally started with anatomy, such as lung, breast or colon. The approval made a molecular property sufficient to define treatment eligibility across different organs, a major step toward precision oncology. The biomarker still identified only a minority of tumours and did not guarantee response.

TIL therapy used immune cells that had already found the tumour, avoiding the need to design one synthetic receptor for every target. Approval in advanced melanoma broadened personalized cell therapy beyond CAR T, but intensive conditioning, specialized centres and manufacturing time remained substantial barriers.

RAS proteins had been considered exceptionally difficult drug targets despite driving many cancers. The approval marked an important precision-therapy advance, not a cure: serious adverse reactions occurred, treatment was studied after earlier therapy, resistance remains possible and the price creates a major access test.

Sequencing can identify mutations unique to a patient's tumour and encode selected targets in an mRNA vaccine. The strategy is highly personalized, but tumour biology still determines whether immune cells can recognize, enter and control the cancer. Conflicting results across tumour types made this setback a necessary milestone rather than a footnote.